BioCentury | Mar 19, 2007
Company News

Biomira management update

...TSX:BRA; BIOM), Edmonton, Alberta Business: Cancer Hired: D. Lynn Kirkpatrick as CSO, formerly CEO of ProlX Pharmaceuticals L.P. WIR...
BioCentury | Jan 8, 2007
Clinical News

PX-12: Phase II started

...are refractory to gemicitabine-containing regimens. BRA gained rights to PX-12 through its 2006 acquisition of ProlX...
BioCentury | Nov 13, 2006
Strategy

Biomira chronicles

...as president, CEO and a director, and appoints Christopher Henney as chairmanS. 10/31/06 - Acquires ProlX...
BioCentury | Nov 13, 2006
Strategy

Smaller shots on goal

...molecules because of the difficulties involved in developing cancer vaccines. Last month, the company acquired ProlX...
...molecules." Last month, BRA did just that, paying C$23.8 million in cash and stock for ProlX...
...CSO Lynn Kirkpatrick, BRA may grow out its pipeline from discovery collaborations in place between ProlX...
BioCentury | Nov 6, 2006
Company News

Biomira, ProlX Pharmaceuticals Corp. deal

...BRA acquired ProlX for $3 million in cash and 17.9 million shares of BRA stock, which...
...of revenues under a potential collaboration for an undisclosed ProlX product in a non-oncology indication. ProlX...
...product in a non-oncology indication. ProlX President and CEO Lynn Kirkpatrick will become BRA's CSO. ProlX's...
BioCentury | Nov 1, 2006
Company News

Biomira acquires cancer company ProlX

...Cancer company Biomira (TSX:BRA; BIOM) acquired ProlX (Tucson, Ariz.) for $3 million in cash and 17.9...
...of revenues under a potential collaboration for an undisclosed ProlX product in a non-oncology indication. ProlX...
...product in a non-oncology indication. ProlX President and CEO Lynn Kirkpatrick will become BRA's CSO. ProlX's...
BioCentury | Jan 30, 2006
Clinical News

PX-12: Phase Ib started

...ProlX began an open-label, dose-escalation, U.S. Phase Ib trial in 24 patients. ProlX Pharmaceuticals LP...
BioCentury | Aug 23, 2004
Company News

ProLx Pharmaceutical Corp., Burnham Institute, University of Arizona, University of Pittsburgh deal

...to develop and market phosphatidylinositol-3-kinase (PI-3K) inhibitors, including lead compound PX-866 and wortmannin. In 2005, ProLx...
...viridin analog, to treat cancer. The institute and universities will share revenues from resulting products. ProLx...
BioCentury | Oct 1, 2001
Clinical News

PX-12: Began Phase I testing

...Small molecule inhibitor of thioredoxin cell growth-promoting protein Indication: Treat metastatic cancer Endpoint: Safety Status: ProlX...
BioCentury | Nov 6, 2000
Company News

ProlX Pharmaceuticals LP other research news

...develop compounds that target biochemical signaling pathways specific to and essential for cancer cell growth. ProlX...
...develop any technology discovered under the grant. The company's PX-12 compound is in preclinical development. ProlX...
Items per page:
1 - 10 of 10
BioCentury | Mar 19, 2007
Company News

Biomira management update

...TSX:BRA; BIOM), Edmonton, Alberta Business: Cancer Hired: D. Lynn Kirkpatrick as CSO, formerly CEO of ProlX Pharmaceuticals L.P. WIR...
BioCentury | Jan 8, 2007
Clinical News

PX-12: Phase II started

...are refractory to gemicitabine-containing regimens. BRA gained rights to PX-12 through its 2006 acquisition of ProlX...
BioCentury | Nov 13, 2006
Strategy

Biomira chronicles

...as president, CEO and a director, and appoints Christopher Henney as chairmanS. 10/31/06 - Acquires ProlX...
BioCentury | Nov 13, 2006
Strategy

Smaller shots on goal

...molecules because of the difficulties involved in developing cancer vaccines. Last month, the company acquired ProlX...
...molecules." Last month, BRA did just that, paying C$23.8 million in cash and stock for ProlX...
...CSO Lynn Kirkpatrick, BRA may grow out its pipeline from discovery collaborations in place between ProlX...
BioCentury | Nov 6, 2006
Company News

Biomira, ProlX Pharmaceuticals Corp. deal

...BRA acquired ProlX for $3 million in cash and 17.9 million shares of BRA stock, which...
...of revenues under a potential collaboration for an undisclosed ProlX product in a non-oncology indication. ProlX...
...product in a non-oncology indication. ProlX President and CEO Lynn Kirkpatrick will become BRA's CSO. ProlX's...
BioCentury | Nov 1, 2006
Company News

Biomira acquires cancer company ProlX

...Cancer company Biomira (TSX:BRA; BIOM) acquired ProlX (Tucson, Ariz.) for $3 million in cash and 17.9...
...of revenues under a potential collaboration for an undisclosed ProlX product in a non-oncology indication. ProlX...
...product in a non-oncology indication. ProlX President and CEO Lynn Kirkpatrick will become BRA's CSO. ProlX's...
BioCentury | Jan 30, 2006
Clinical News

PX-12: Phase Ib started

...ProlX began an open-label, dose-escalation, U.S. Phase Ib trial in 24 patients. ProlX Pharmaceuticals LP...
BioCentury | Aug 23, 2004
Company News

ProLx Pharmaceutical Corp., Burnham Institute, University of Arizona, University of Pittsburgh deal

...to develop and market phosphatidylinositol-3-kinase (PI-3K) inhibitors, including lead compound PX-866 and wortmannin. In 2005, ProLx...
...viridin analog, to treat cancer. The institute and universities will share revenues from resulting products. ProLx...
BioCentury | Oct 1, 2001
Clinical News

PX-12: Began Phase I testing

...Small molecule inhibitor of thioredoxin cell growth-promoting protein Indication: Treat metastatic cancer Endpoint: Safety Status: ProlX...
BioCentury | Nov 6, 2000
Company News

ProlX Pharmaceuticals LP other research news

...develop compounds that target biochemical signaling pathways specific to and essential for cancer cell growth. ProlX...
...develop any technology discovered under the grant. The company's PX-12 compound is in preclinical development. ProlX...
Items per page:
1 - 10 of 10